Efficacy and Safety of GP Chemotherapy Combined With Tislelizumab Neoadjuvant Therapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma: a Single-arm, Phase 2 Trial
Latest Information Update: 09 Jul 2022
At a glance
- Drugs Tislelizumab (Primary) ; Antineoplastics; Cisplatin; Gemcitabine; Immunotherapies
- Indications Carcinoma; Nasopharyngeal cancer
- Focus Therapeutic Use
- 07 Jun 2022 Results assessing efficacy and safety of neoadjuvant treatment with tislelizumab in previously untreated locoregionally advanced nasopharyngeal carcinoma, presented at the 58th Annual Meeting of the American Society of Clinical Oncology.
- 15 Apr 2021 Status changed from not yet recruiting to recruiting.
- 07 Apr 2021 New trial record